Condition
Axillary Metastases
Total Trials
5
Recruiting
3
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Recruiting3
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07085442Recruiting
Audit of Targeted Sentinel Node Biopsy (TSNB) in Patients With Limited Nodal Disease Undergoing Primary Surgery
NCT06339658Recruiting
ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
NCT04671511Not ApplicableRecruiting
Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer
NCT03630913Not ApplicableUnknown
Sentinel Lymph Node After Neoadjuvant Chemotherapy in Breast Carcinoma
NCT03740815Not ApplicableCompleted
Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection
Showing all 5 trials